Who talks to their neighbour? +SSA / Ro talk differently to nearby cells in #SjD #salivary #glands vs NEG Ro SjD Ro52 acts differently than Ro60 ?implications for Rx response? 🤷‍♀️ #ACR25 @RheumNow @ACRheum #Sjogren’s Abst#1684 #ACRBest! Elegant work from Sara McCoy https://t.co/UWUKAxi0UW

How many patients do you need to treat to prevent one RA conversion in at-risk individuals? APPIPRA and ALTO Interception studies, long term data Number Necessary to Treat to prevent 1 RA conversion across time: 1yr = 4 2yrs = 7 3, 4, 5 yrs = 9 6 yrs = 11 #ACR25 #ABSTRACT1678 https://t.co/GBzUJG8jVk

DYK? A bipartite ilium is a common SIJ variant. More common among women. SpA mimics involving biomechanical stress: BME & sclerosis 🔸OCI - assoc w/ multiparity, obesity 🔸Degenerative dse #ACR25 @RheumNow https://t.co/IoZepAJKJ6

So who with inflamm arthralgias might benefit from abatacept, in terms of delaying RA onset? ALTO study (APIPPRA continuation) 1y abatacept then follow If autoAb x5 (RF, ACPA IgG, IgA, anti-CarP, AAPA): sustained delay of RA If not: benefit only on Rx #ACR25 ABST1678 @RheumNow https://t.co/3Pc5ZLzVf6

#ACR25 Abstr#1401 Sjogren’s #SjD is definitely not a benign disease! Real world study using US database showed high disease burden within 12 mths of diagnosis (i.e. healthcare resource use). GC use was high (~50%). Better therapy is needed to improve outcomes @RheumNow https://t.co/MI3vQ5LByr

TNFi induction first year in RA leads to: - less D2T RA at 5y - more sustained remission from 10y onward - less DMARD utilization - less healthcare utilization in these real-world matched cohorts given biosimilar prices, this might be worth considering #ACR25 ABST1677 @RheumNow https://t.co/uL9nHtLkXZ

Early TNFi treatment leads to -Less D2T at 5 yrs -More sustained remission at 10yrs -Less bDMARD escalation at 5yrs -More DMARD free remission at 5yrs and 10 yrs -20% reduction annual healths costs -11 mo delay in ttmt escalation Safety data were not presented #ACR25 https://t.co/jPMGUGPtqP

SELECT-COMPARE RA UPA vs. ADA What do we learn from 7 years data? Not much Patients who did well on the first drug, keep doing well Patients who required switching for primary failure don't do as well, w/ 26% pts reaching DAS remission in UPA + MTX vs. 16% in ADA + MTX gp No https://t.co/JLUTRZuZOm

Primary CNS vasculitis: what else causes vessel wall enhancement on dedicated brain MRI? From Dr. Hajj-Ali https://t.co/v5ZtyezX3x

~1 in 6 pts with #sarcoidosis May have #cardiac involvemt 1/3 respond to #MTX + #steroids Followed by repeat #PET Failures get 👇 #infliximab >#adalimumab 👇 #JAKi Better survival >yrs ago R heart involved ⬆️risk of MTX nonresponse #ACR25 @RheumNow @ACRheum abst#1664 #ACRbest https://t.co/kYt9JRNSVH

In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, either: - during 1y of treatment - in 2y follow-up https://t.co/gtzNiSmutb but StopRA will give us plenty of insights - data is never wasted #ACR25 ABST1674 @RheumNow https://t.co/DDZib5VGtX

SELECT-COMPARE (upadacitinib vs adallimumab in mod-severe RA, no CV enrichment) 7y data: safety profiles very similar, except for: - zoster - CK rise - lymphopenia - hepatic disorder In the general RA population, no new JAKi safety signals #ACR25 ABST1676 @RheumNow https://t.co/BA2JxONGfa